The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2022 | Unanswered questions in treating lung cancer with immunotherapy
Jia Luo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the optimal time to stop immunotherapy as well as which groups of patients with lung cancer should receive extra immunotherapy. A majority of trials cease immunotherapy treatment after two years, which is supported by data from the CheckMate 153 trial (NCT02066636), where one year of immunotherapy was shown to be insufficient. In the CheckMate 227 trial (NCT02477826), which assessed nivolumab and ipilimumab in patients with non-small cell lung cancer (NSCLC), patients with a high tumor mutation burden but have a low PD-L1 expression may benefit from two checkpoint inhibitors. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).
